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background: Male infertility caused by a maturation arrest of spermatogenesis is a condition with an abrupt stop in spermatogenesis,
mostly at the level of primary spermatocytes. The etiology remains largely unknown.
methods: We focused on patients with a complete arrest at the spermatocyte level (n ¼ 9) and used array comparative genomic hy-
bridization to screen for deletions or duplications that might be associated with maturation arrest. Interesting copy number variations (CNVs)
were further examined by using quantitative PCR. Where appropriate, the expression pattern was analyzed in multiple human tissues includ-
ing the testis.
results: A total of 227 CNVs were detected in the patient group. After the elimination of CNVs that were also present in the control
group or that were not likely to be involved in male infertility, the remaining 11 regions were investigated more in detail. We first determined
the expression pattern of seven genes, for which expression had not been reported to be investigated in testicular tissue, after which one
region could be eliminated. Next, all 10 promising candidate regions were analyzed by quantitative PCR in a control population.
conclusions: Eight deletions/duplications were absent in our control group, and therefore might be linked with the male infertility in
our patients. One of these alterations, however, has been detected in a proven fertile father group. Further research is necessary to deter-
mine the relationship between the observed genomic alterations and maturation arrest of spermatogenesis. Furthermore, several of the
above genes have not been studied at the functional level and consequently, more research is required to determine their role in
spermatogenesis.
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Introduction
Infertility, affecting 10–15% of couples, is a worldwide problem.
Roughly half of the cases can be assigned to a male factor, mostly diag-
nosed by decreased sperm numbers or the complete absence of
mature spermatozoa in the patients’ ejaculate. Many iatrogenic and
non-iatrogenic causes are known, and environmental risk factors are
under scrutiny. Furthermore, combinations of acquired, environmental
and congenital factors are also expected, which hampers the diagnosis.
For some of the patients, a unique genetic defect is predicted. Until
now, genetic causes of male infertility have especially been detected
in men with a specific testicular phenotype, such as maturation
arrest of spermatogenesis, or with sperm defects such as globozoos-
permia (Massart et al., 2012). It remains unsure, however, for what
percentage of infertile men a single genetic defect is anticipated.
Special attention should be paid to these hereditary causes, since
they might potentially be transmitted to the next generation with
assisted reproduction when sperm cells are available. So far, the
only routine tests performed in the clinical work-up of male infertility
are karyotype analysis, screening for cystic fibrosis transmembrane
conductance regulator mutations (in case of suspicion of congenital
bilateral absence of the vas deference) and Yq microdeletion analysis
(Lissens et al., 1996; McLachlan and O’Bryan, 2010). Some laborator-
ies are now also routinely testing for the presence of gr/gr deletions,
which are a known risk factor for male infertility (Stouffs et al., 2011a).
During the last decade, many efforts have been made in our lab, as
well as worldwide, to identify mutations in spermatogenesis genes
(Tüttelmann et al., 2007; Nuti and Krausz, 2008). The outcome has
been mostly disappointing, and if a potential mutation was found,
often the results could not be confirmed by other research groups.
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Exceptions come from a few studies in consanguineous families and/
or from patients with specific semen abnormalities (Dam et al., 2007;
Dieterich et al., 2007). Yet, for infertility studies, it is hard to find large
families. Moreover, it is expected that mutations are present in a
whole range of genes at different positions, and mutation studies are
limited by the selection of genes for analysis. This selection is mostly
based on previous functional studies and/or knock-out mice models
(Yatsenko et al., 2010). However, from recent expression studies,
it became evident that many genes have not been studied at the
functional level (Tang et al., 2007; Xiao et al., 2008).
In mice, one approach to overcome the manual selection of genes
with a known function in spermatogenesis is through ‘ENU studies’. In
these studies, a phenotype-driven approach is used, and therefore, a
gene selection bias is avoided. The chemical mutagen N-ethyl-
N-nitrosourea (ENU) is used to create random mutations in the
mouse genome. After a selection on the phenotype (male infertility),
the underlying mutated gene is searched (Jamsai and O’Bryan, 2010).
This approach is useful in identifying new genes potentially involved in
male infertility. However, it cannot be used in human studies.
In order to study genetic defects in the human, and to overcome
the selection bias, we decided to investigate whether array compara-
tive genomic hybridization (array CGH) might be a useful tool in study-
ing genetics of male infertility. By using array CGH, deletions and
duplications/amplifications throughout the complete genome can be
explored. As a consequence, there is no limit to the selection of
genes. Our aims were 2-fold: first of all, we wanted to know
whether deletions or duplications specifically associated with male in-
fertility can be detected in a patient’s genome, and second we wanted
to investigate whether array CGH could be applied in a routine setting
as part of the clinical work-up.
For this pilot study, we focused on the presence of presumed ‘single
defects’ that are causative for male infertility, i.e. abnormalities (dele-
tions/duplications) in individual genes (or regions) that are directly
linked to the observed fertility problems. For this purpose, we inves-
tigated a small, but well-defined group of patients showing meiotic
arrest in spermatogenesis. In this patient group, it is more likely that
an alteration (copy number variation, CNV) in a single region or




Genomic DNA was isolated from peripheral blood using Qiagen’s ‘QIamp
Blood Maxi Kit Protocol’ (Qiagen, The Netherlands) or using magnetic
purification with the ‘Multiprobe II Plus EX + Gripper’ liquid handling
robot and ‘Chemagic Magnetic Separation Module I’ (PerkinElmer,
Belgium).
DNA samples from a total of nine azoospermic patients presenting for
infertility treatment and showing maturation arrest of spermatogenesis
were included in the present study. For all patients, testicular sperm ex-
traction (TESE) was performed, during which a testicular biopsy was
also taken for histological examination within the frame of their fertility
work-up (Tournaye et al., 1997). All patients showed a meiotic arrest of
spermatogenesis. No spermatozoa were found, either in patients’ ejacu-
lates, or during TESE or histological examination. In all patients, the karyo-
type was normal, and no Yq microdeletions were detected. No gr/gr
deletions were detected in these patients. Patients with a varicocoele or
history of cryptorchidism were excluded from this study. A final selection
criterion was based on the origin of the patients: only Caucasians origin-
ating from Belgium or the Netherlands were included.
For the control group, DNA samples from men with normozoospermia,
defined by routine sperm analysis, were used. These men were also of
Caucasian origin from Belgium or the Netherlands. In a first part of the
study, 20 control samples were analyzed alongside with the patients
through array CGH. In a second part of the study, up to 130 extra controls
were investigated by qPCR: first, 70 controls were tested. When no
changes were detected in this group of 70 controls, 60 more controls
were analyzed in a second round of qPCRs in order to increase the
statistical power (more information is provided in Supplementary data,
Fig. S1).
Array CGH
Array CGH analysis was performed using standard methods described
(Buysse et al., 2009). In brief, 300 ng of genomic DNA was labeled with
Cy3-dCTP or Cy5-dCTP (GE Healthcare, Belgium) using a Bioprime
array CGH genomic labeling system (Invitrogen, Belgium). For the labeling,
we used the ‘triangle method’: DNA samples from patients and controls
were labeled and hybridized using a dye swap in trios consisting of at
least one control per triangle. Samples were hybridized on 244K arrays
(design ID 014693, Agilent, Belgium) for 40 h at 658C. After washing,
the samples were scanned at 5 mm resolution using a DNA microarray
scanner G2505B (Agilent). The scan images were analyzed using the
feature extraction software 9.5.3.1 (Agilent) and further analyzed with
‘arrayCGHbase’ (Menten et al., 2005). CNVs were taken into consider-
ation when two or more flanking probes exceeded a value of the intensity
ratios+ four times the standard deviation of the log 2 of all intensity ratios
for that experiment. Always two experiments investigating the same
sample with a dye swap were compared and only when an alteration
was present in both experiments, the region was included for further ana-
lysis. Inconsistencies were inspected manually.
Quantitative PCR
qPCR was performed on genomic DNA using predesigned Taqman Copy
Number Assays (Applied Biosystems, Belgium) according to instructions of
the manufacturer. Samples were run on the 7500 real-time PCR system
(Applied Biosystems) and analyzed using CopyCaller Software provided
by Applied Biosystems. The assays used are reported in Supplementary
data, Table SI. In each assay, we have included the patient with the alter-
ation detected by array CGH.
PCR analysis to detect the presence
of TUSC3
For the TUSC3 gene, primers were designed in exon 1 (forward:
ACCGGATGCTCTGTCAGTCT and reverse: GCCAAGGGGATC
CATTCTAC) and intron 1 (forward: TGAGGAAGGATGGCTGAAT
CAAGGT and reverse: AGCCAAGCTGAATTCAAGTGCCA) and
were synthesized by IDT (Belgium). PCRs were performed in a 50 ml
mix containing 250 ng of DNA, 1 × PCR Buffer II (Applied Biosystems),
2 mmol/l of MgCl2 (Applied Biosystems), 0.2 mmol/l of each dNTP (GE
Healthcare), 1 mmol/l of each primer and 1.25 units of Taq polymerase
(Applied Biosystems). Thermocycling conditions consisted of an initial
denaturation of 5 min at 948C, 30 or 35 cycles of 1 min at 948C, 1 min
at 608C and 2 min at 728C and a final extension for 7 min at 728C.
PCR products were analyzed on a 2% agarose gel.
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The reference sequences from Genbank (NM_144713.3 for FAM82A1;
NM_001113434.3 for c17orf51; NM_013386.3 for SLC25A24;
NM_012240.2 for SIRT4) and genomic sequences from Ensembl
(http://www.ensembl.org) were used as references to compare with
our data. Primers were designed to be able to amplify and sequence the
entire coding region and parts of the flanking introns (Supplementary
data, Table SII) and were synthesized by IDT. PCRs and thermocycling
conditions were as described above, except for the annealing temperature
which was optimized for each reaction. After purification, all samples were
sequenced with the primers used for amplification and run on the
ABI3130xl Genetic Analyser (Applied Biosystems).
Single nucleotide changes were analyzed through Alamut (Interactive
Biosoftware).
RNA expression
The presence of RNA in testicular tissues was investigated using home-
made RNA. Fresh testicular tissue was obtained from patients who
came to the hospital for vasectomy repair and who signed an informed
consent. The histology was determined on a second biopsy and showed
normal spermatogenesis. RNA was extracted using the RNeasy Mini kit
(Qiagen, Belgium) after which cDNA was prepared using the Transcriptor
First Strand cDNA Synthesis Kit (Roche, Belgium). Primers for amplifica-
tion of cDNA were designed according to the reference sequences and
were overlapping at least one intron/exon boundary (Supplementary
data, Table SIII). All amplified fragments from testicular tissues were
sequenced to confirm specific amplification.
The expression of RNA in multiple human tissues was analyzed using
the Human MTC panel I and II (Clontech, Westburg, Belgium).
Proven fertile parents
In order to have access to more control data, the results of our array CGH
analysis were compared with information gained from proven fertile
parents. These parents were analyzed in the Center of Medical Genetics
from the Ghent University Hospital in view of the investigation of a child
with phenotypic abnormalities and/or mental retardation. The data
were obtained using 44K or 105K arrays (Agilent) by applying the same
protocol as described in this paper.
Statistical analysis
For regions analyzed by qPCR, the frequency of the rearrangements
in patients and controls were compared using x2 test. For this
test, we took into consideration all patients (n ¼ 9) and controls
(n ¼ 90 or n ¼ 150) analyzed by qPCR and array CGH.
Results
Nine patients with a complete meiotic arrest in spermatogenesis and
20 control patients with normal sperm parameters were analyzed
using 244K oligonucleotide arrays. Overall, when considering CNVs
of at least two consecutive markers, the average and median
number of detected CNVs were 24.3 and 26.5 in the control group
and 25.3 and 26 in the patient group. These data do not differ statis-
tically. In the patient group, the total number of variations detected
was 227 (Fig. 1).
As a first step, we compared the data obtained from patients and
controls, and excluded regions that were either deleted or amplified
in both patients and controls. If a region was deleted in a patient,
but amplified in a control (or vice versa), this region was kept for
Figure 1 Flow chart of the elimination steps in the analysis of the results obtained through array CGH.
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further analysis. We excluded regions that do not contain any known
genes (NCBI build 37), or only contain pseudogenes or non-coding
RNA. After this analysis, 30 regions or genes remained in the
patient group for more detailed investigation (Supplementary data,
Table SIV).
The genes AGBL4 in 1p33, FHIT in 3p14.2, QKI in 6q26, PRKG1 in
10q11.23 and CTNNA3 in 10q21.1 were not further investigated
since the deletions in these genes were completely intronic. For
these genes, we looked at the predicted maximum sizes of the dele-
tions, and could conclude that the deletions were always restricted to
an intron. One exception was TUSC3 in 8p22. For this gene, the
minimal deleted region was limited to intron 1. However, the last frag-
ment present 5′ of the gene was located 5′ of exon 1. Therefore, it
could not be concluded whether exon 1 was deleted or not. This
patient (EMA7) was predicted to have a homozygous deletion.
Primers were designed in the minimal region that was absent accord-
ing to array CGH. As predicted, this primer failed to amplify in the
DNA of EMA7, whereas PCR amplification was observed in a positive
control. In contrast, PCR amplification was observed for a fragment
located in exon 1. We could thus conclude that the deletion was
limited to intron 1, and therefore, this region was not taken into
further consideration.
We also excluded regions with genes with a known function, not
involved in spermatogenesis or genes that are not expressed in testicu-
lar tissue (Supplementary data, Table SIV). We further eliminated a
region on the X chromosome (Xq28) containing PNMA6A (paraneo-
plastic antigen like 6A) and MAGEA1 (melanoma antigen family A, 1).
MAGEA1 is expressed in testicular tissue. Yet, multiple copies of this
gene family are located in this region, and therefore, we hypothesize
that one extra duplication would not influence the function of this
gene (Stevenson et al., 2007; Stouffs et al., 2009). Furthermore, due
to the presence of multiple copies of these genes, Taqman Copy
Number Assays for qPCR analyses are currently not available. Similar-
ly, region 21p11.1 contains multiple copies of genes belonging to the
BAGE (B melanoma antigen) family of cancer-testis (CT) genes. These
CT genes have been recently generated and amplified during evolution
(Ruault et al., 2003).
Remarkably, one large duplication of 114 markers located in
chromosomal region 1q21.1 was also detected. This region contains
several genes and pseudogenes. At first sight, no testis-specific gene
was located in this region. A search of the literature showed that dupli-
cations of this region have been reported and might be associated with
macrocephaly and developmental disorders or schizophrenia
(Brunetti-Pierri et al., 2008; Mefford et al., 2008). Yet, the same dele-
tions and duplications were also observed in apparently healthy
parents, showing that rearrangements of this region are not associated
with azoospermia. Similarly, a large duplication encompassing
8p23.1p23.2 has been described in a mother and child (Glancy
et al., 2009), partly involving the CSMD1 gene. Although the duplica-
tion size was different and the duplication was transmitted through
the mother, we predicted that a duplication of CSMD1 is not import-
ant for spermatogenesis and therefore we did not select this gene for
further analysis.
After this elimination, we ended up with 11 regions for further ana-
lysis (Table I). Of the genes located in these regions, SH3D21
(C1ORF113), C17ORF51, CLEC18B, FAM82A1 and NBP4F have not
been studied before. The gene TSSC1 has been described previously,
but the expression in the testis remains unknown (Hu et al., 1997;
Scelfo et al., 1998). The expression of THRAP3 has already been
described in multiple tissues, but testicular tissue was not included
(Ito et al., 1999). Therefore, this gene was also included in our expres-
sion study. We first analyzed, by PCR and sequence analysis, whether
these genes are expressed in testicular tissues and could show that all
genes, except CLEC18B were expressed in the testis. For CLEC18B,
.............................................................................................................................................................................................
Table I Overview of CNVs selected for further analyses.
Patient Del/dupl Region Begin End # Genes*
1 EMA8 Duplication 1p34.3p34.3 36 716 865 36 777 255 8 THRAP3/C1orf113
2 EMA3 Deletion 1p13.3p13.3 108 713 464 108 900 204 9 SLC25A24/NBPF4
3 EMA7 Duplication 1p13.2p13.2 114 657 656 114 814 238 10 SYT6
4 EMA3 Duplication 2p25.2p25.2 3 062 188 3 325 509 23 TSSC1
5 EMA18 Deletion 2p22.2p22.2 38 085 399 38 180 014 7 FAM82A1
6 EMA18 Duplication 3q24q24 146 114 122 146 191 793 8 PLSCR2
7 CENS79 Duplication 5q13.2q13.2 69 705 562 70 657 747 7 SERF1A/SERF1B/SMN1/SMN2/NAIP/GTF2H2
CENS93 Duplication 5q13.2q13.2 69 732 192 70 386 541 4 SERF1A/SERF1B/SMN1/SMN2/NAIP/GTF2H2
EMA12 Deletion 5q13.2q13.2 70 308 101 70 309 855 2 NAIP
EMA18 Deletion 5q13.2q13.2 70 308 101 70 309 855 2 NAIP
EMA7 Duplication 5q13.2q13.2 70 308 101 70 309 855 2 NAIP
8 EMA18 Deletion 12q24.31q24.31 120 734 605 120 755 841 5 SIRT4
9 EMA8 Duplication 15q15.3q15.3 43 888 927 43 950 720 10 CKMT1B/STRC/CATSPER2
10 EMA3 Deletion 16q22.3q22.3 74 375 794 74 455 311 4 CLEC18B
11 CENS79 Duplication 17p11.2p11.2 21 370 330 21 453 044 7 C17orf51
EMA2 Deletion 17p11.2p11.2 21 370 330 21 501 929 10 C17orf51
*Pseudogenes were removed from this list.
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our primers were able to amplify CLEC18A, CLEC18B and CLEC18C.
Yet, based on the sequence, a distinction between the three genes can
be made. We were able to conclude that both CLEC18A and
CLEC18C are expressed in testicular tissue, but CLEC18B is not.
As a consequence, we could eliminate the region containing the
CLEC18B gene from additional analyses.
We further looked at the expression of the genes C1ORF113,
C17ORF51, FAM82A1, NBP4F and TSSC1 in different tissues (Supple-
mentary data, Fig. S2A–E). All genes were expressed in most of the
tissues analyzed. For C1ORF113, C17ORF51 and FAM82A1, a high
expression was observed in testicular tissue (although this was not
quantitatively tested).
Finally, there were 10 remaining regions that are potentially related
to the fertility problems in our patients (Table I). To further investigate
the relationship between the observed deletions/duplications and
male infertility, we analyzed more controls by using quantitative PCR
with pre-designed copy number assays. All alterations observed by
array CGH could be confirmed by qPCR. The 10 regions are
described below. In this description, we always mention the minimal
deletion/duplication. However, one should also take into consider-
ation that the actual region involved might be larger.
Region 1p34.3, position
36 716 865–36 777 255, containing
THRAP3 and C1ORF113
A duplication of this region was detected in EMA8. In this region, the
majority (exons 2–12) of the THRAP3 gene is duplicated, as well as
exons 1–10 of the C1ORF113 (¼SH3D21) gene (according to the
RefSeq sequences NM_005119.3 and NM_001162530.1). A total of
130 controls were tested using a Taqman Copy Number assay
located in exon 4 of the THRAP3 gene (Supplementary data,
Fig. S3). None of the controls tested had a duplication or deletion
of this region (P , 0.01).
Region 1p13.3, position
108 713 464–108 900 204 containing
SLC25A24 (5SCAMC15APC1) and NBPF4
A heterozygous deletion of this region was detected in patient
EMA3. The deletion encompasses exons 1–3 of SLC25A24
(reference sequences NM_013386 for transcript variant 1 and
NM_213651 for transcript variant 2) and the complete NBPF4 gene
(NM_001143989.2). A first Taqman Copy Number Assay was
located at position 108735360 (NCBI build 37, exon 2). However,
this fragment also appeared to be absent in 31% (22/70) of the controls
tested. Since only a single patient and no controls with a deletion were
detected by array CGH, we randomly picked 11 controls tested by array
CGH to test again by qPCR. As expected, three of these controls (27%)
had a deletion of the region where the Taqman Copy Number Assay
was located. It was therefore presumed that smaller deletions are
present in this region in a high percentage of the population. The data-
base of genomic variants (projects.tcag.ca/variation/) indeed showed a
small deletion that was limited to this region. Therefore, a new assay,
located between the genes SLC25A24 and NBPF4 was studied. No pre-
designed assay was located in the NBPF4 gene. By analyzing 130 controls
with this new assay, no deletion could be detected (P , 0.01). The
remaining copy of the SLC25A24 gene was sequenced in patient
EMA3 (having a heterozygous deletion). No changes were detected in
the exons and part of the flanking introns of this gene.
Region 1p13.2, position
114 657 656–114 814 238, containing SYT6
In EMA7, a duplication of this region was observed. This duplication
involves exons 6–8 of the SYT6 gene (NM_205848.2). A total of
130 controls who were tested by qPCR all showed a normal copy
number (P , 0.01).
Region 2p25.2, position
3 062 188–3 325 509, containing TSSC1
In EMA3, exons 4–9 of TSSC1 are duplicated. In 70 control samples
tested by qPCR with an assay located in exon 6 of the TSSC1 gene,
one control sample was found to have a duplication. Taking all 90 con-
trols tested (70 by qPCR and 20 by array CGH) into consideration, no
(statistical) difference was detected. Furthermore, in a diagnostic setting,
we have detected a duplication in a child and his (proven) fertile father.
Region 2p22.2, position
38 085 399–38 180 014, containing FAM82A1
The first five exons of the FAM82A1 gene (NM_144713.3) were pre-
dicted to be deleted in EMA18. We tested a total of 130 controls for
the presence of copy number alterations in FAM82A1. We detected
one man with a duplication of the region where the assay was
located. However, no deletions were detected (P , 0.01). We also
sequenced all exons and part of the flanking introns of the remaining
gene copy in patient EMA18, but no mutations were detected.
Region 3q24, position
146 114 122–146 191 793, containing PLSCR2
and LOC440981
The duplication of this region involves exons 2–9 of the PLSCR2 gene
and exons 1–3 of the hypothetical protein LOC440981. The assay
used to search for deletions/duplications in control samples was
located in exon 5 of the PLSCR2 gene. The duplication in EMA18
could be confirmed, but no other duplications or deletions were
detected in 130 controls tested (P , 0.01).
Region 5q13.2, position
70 308 101–70 309 855, containing NAIP
Through array CGH, multiple duplications have been detected encom-
passing this region in patients and controls. However, two deletions
(minimal size: 1754 bp and maximal size: 654 kb) were only detected
in two patients and in none of the controls. This deletion involves only
exon 4 (minimum deletion size), containing the start codon of the
gene. An assay located in exon 4 was ordered to analyze control
samples. Obviously, also larger duplications, as detected using array
CGH, will be visualized when using this assay. There were 70 controls
tested. In this group, four controls had only a single copy of this region.
As expected, we also detected multiple controls with three (n ¼ 9)
copies of this region. Taking into consideration all controls tested
(n ¼ 90), significantly more deletions were detected in the patient
group (P ¼ 0.03).
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Region 12q24.31, position 120 734 605–
120 755 841, containing SIRT4
This deletion removes the complete SIRT4 gene in patient EMA18.
The Taqman Copy Number Assay was chosen in exon 2 (containing
the start codon). None of the controls tested had a deletion (P ,
0.01). Therefore, we also sequenced the remaining copy of the
SIRT4 gene in EMA18. No mutations could be detected.
Region 15q15.3, position
43 888 927–43 950 720, containing CKMT1B,
STRC and CATSPER2
The duplication of this region includes part of CKMT1B (exons 8–10)
and the complete STRC and CATSPER2 genes. No Taqman Copy
Number Assay was located in the CKMT1B gene, and there was
only a single assay for STRC. The assay chosen in the CATSPER2
gene was located in exon 6. The duplication in EMA8 could be con-
firmed, but no other duplications were detected (P , 0.01). We did
observe, however, two deletions in the control group consisting of
130 men. In a diagnostic setting, however, .25 duplications have
been detected involving the CATSPER2 gene, making this a highly poly-
morphic region.
Region 17p11.2, position
21 370 330–21 501 929, containing C17ORF51
This deletion encompasses the complete gene in patient EMA2.
Through array CGH, one control was detected with a duplication of
this region. By using qPCR with an assay located in exon 2, we
detected one additional duplication out of the 130 controls tested.
However, no deletions were observed (P , 0.01). The remaining
allele of C17ORF51 was sequenced in patient EMA2, but no alterations
were detected in this copy of the gene.
Discussion
This study is describing CNVs in association with the genetic back-
ground of male infertility. Since causes of male infertility are very het-
erogeneous, we decided to investigate a small yet uniform group of
patients: men with a maturation arrest of spermatogenesis. For this
patient group, it is more likely that a genetic defect is the cause of
their fertility problem. It is known that Yq microdeletions might
cause maturation arrest of spermatogenesis, especially in case of an
AZFb deletion (Kleiman et al., 2011). Furthermore, mutations in the
meiosis gene SYCP3 have been described. Yet, in our patients with
maturation arrest of spermatogenesis, no changes causing alterations
at the protein level could be detected (Stouffs et al., 2005; Stouffs
et al., 2011b). Since mutation screening has some limitations, we
decided to use array CGH to screen for deletions and duplications
throughout the entire genome. Array CGH has the advantage of
having no selection bias at the gene level. Therefore, our analysis is
not limited to genes with a known function in spermatogenesis.
However, array CGH too suffers from some limitations. First of all,
the resolution is a limiting factor. We used 244K arrays with
236 381 probes spread over the genome with an average spacing of
8.9 kb (7.4 kb in RefSeq genes). Small deletions or duplications may
be missed as well as point-mutations. Nowadays, high-resolution
arrays with up to 2 million probes (Nimblegen) are commercially avail-
able. Furthermore, it is impossible with array CGH analysis to detect
balanced inversions or translocations that might disrupt genes which
are essential for meiosis or spermatogenesis. Yet, for all our patients,
a karyotype analysis has been performed and hence, large rearrange-
ments could be excluded.
In our elimination steps, we only considered protein coding genes,
and all CNVs that were present in controls were also removed. As a
consequence, potential ‘risk factors’ might be eliminated. However,
the presence of such ‘risk factors’ influencing male infertility are
more expected in oligozoospermic men than in azoospermic men
with a maturation arrest of spermatogenesis. We are well aware
that regulatory elements or non-coding RNAs could potentially influ-
ence spermatogenesis. It is even thought that small RNAs play an im-
portant role during spermatogenesis (He et al., 2009).Yet, this new
area needs largely to be investigated. For this pilot study, we
wanted to investigate whether CNVs of protein coding genes can
be detected in infertile men.
All potentially interesting regions were further investigated through
real-time PCR using Taqman Copy Number Assays. As such, all
observed rearrangements were confirmed, and more controls could
be analyzed. Where possible, we have chosen an assay located in
an exon and in the middle of the rearrangements, to be as represen-
tative as possible for that region. When no changes are detected for
the corresponding region, it can be concluded that the rearrangement
observed in the patient was not present in the control group.
However, when a deletion/duplication was detected in patient(s) as
well as control(s), it is possible but not sure that the same alterations
are present in patients and controls. Yet, the rearrangements in the
genes TSSC1 and NAIP are rather small, and therefore the Taqman
Copy Number Assay is more likely to be representative for the com-
plete region. For both regions, we detected at least one alteration in
our normozoospermic control group. Furthermore, alterations in the
regions 2p25.2 (TSSC1) were also detected in a diagnostic setting.
Deletions of the region containing the NAIP gene (5q13.2) were
observed more frequently in our patient group compared with the
control group. Possibly, these deletions should be considered as
‘risk factors’. However, the number of patients and controls analyzed
remains too small. Overall, we believe that these regions can be
excluded as being causative of the fertility problems.
Eight rearrangements might be linked to the fertility problems of our
patients, as they are not detected in our normozoospermic control
group: four are deleted regions and four are duplications. The
regions with a deletion were of particular interest since the region/
gene is disrupted or completely removed. The consequences of dupli-
cations are harder to predict. For all regions with a deletion, we have
sequenced the remaining copy of the gene of interest.
A first region, located on chromosomeband 1p34.3 contains the
genes THRAP3 and SH3D21 (¼C1ORF113). The latter gene has not
been studied before. We could show that this gene is expressed in
most of the tissues analyzed, including testis. Yet, its more specific ex-
pression pattern and function remain unknown. An SH3 domain is
predicted in this protein, which is an essential domain for multiple bio-
logical processes (Mayer, 2001). Also the THRAP3 gene is ubiquitously
expressed, with highest expression in skeletal muscle and ovary
(Nagase et al., 1996; Ito et al., 1999). THRAP3 is involved in
pre-mRNA splicing, an important step during spermatogenesis (Lee
926 Stouffs et al.







et al., 2010). A total of 20 controls have been tested by array CGH
and 130 controls were analyzed by qPCR. None of these 150 controls
tested had a duplication or deletion of this region. As a consequence, a
gain in copy number of THRAP3 and/or SH3D21 might be linked to
the fertility problems observed in EMA8.
A second region was located at chromosomeband 1p13.3 and con-
tains two genes, SLC25A24 and NBPF4. The latter gene belongs to a
family of at least 22 NBPF genes that have recently been duplicated in
evolution, with the majority of the copies located on chromosome 1
(Vandepoele et al., 2005). Therefore, it is less likely that a deletion
of one copy of this family will have a large impact on the fertility
status of the patients. The SLC25A24 gene belongs to a family of
genes that encode for mitochondrial carriers involved in the transport
of adenine nucleotides (Fiermonte et al., 2004). The SLC25A24
(¼SCAMC1¼APC1) gene is highly expressed in testicular tissue
(Fiermonte et al., 2004). Therefore, this gene is a good candidate
(in)fertility gene. There are two splice variants of the SLC25A24
gene. The first Taqman Copy Number Assay that we tried was
located in exon 2 which is the first exon in NM_213651 (variant 2)
and includes the start codon. In transcript variant 1, this exon is
missing. We noticed a high frequency of deletions involving this
region in patients as well as in controls. A more detailed look at the
database of genomic variants showed that this region was often involved
in rearrangements. These rearrangements are limited to exon 2, and
part of the flanking introns. No probes representing this region were
located on the 244K arrays we used. Due to the high frequency of het-
erozygous deletions of this region, the importance of transcript variant 2
might be questioned. In our patient, EMA3, a heterozygous change was
also detected, but involving exons 1–3. Therefore, also the start codon
of transcript variant 1 is missing. The remaining gene copy was
sequenced, but no changes were detected.
In a third interesting region, the SYT6 gene was partly duplicated. At
first, this gene was reported not to be transcribed in spermatogenesis,
but later a function in the acrosome reaction was described (Craxton
and Goedert, 1999; Michaut et al., 2001). Since it remains unsure from
which stage onwards the SYT6 gene is present in spermatogenesis, we
included this gene for further analyses. Yet, defects in a gene involved
in the acrosome reaction will most likely not cause a maturation arrest
of spermatogenesis at the meiotic level.
Similarly, we observed a duplication in a region containing the
PLSCR2 gene and a hypothetical protein. The region including the com-
plete open reading frame of PLSCR2, was duplicated in patient EMA18,
but not in the 150 controls tested in total. The PLSCR2 gene shows a
testis-specific expression pattern, and might be involved in sperm cap-
acitation (Wiedmer et al., 2000; de Vries et al., 2003). Yet, it remains
unsure whether the PLSCR2 protein has a function in earlier steps of
spermatogenesis and consequently whether duplications in this gene
might explain the maturation arrest of spermatogenesis found in
patient EMA18.
Furthermore, we detected a duplication involving the CATSPER2
gene. This gene also has a function later in spermatogenesis; it is es-
sential for sperm motility. Yet, for the CATSPER2 protein, the expres-
sion has been detected from spermatocytes onwards (Quill et al.,
2001). Consequently, a gain in copy number of this gene might
force the spermatocytes to stop developing and thereby causing mat-
uration arrest of spermatogenesis. Yet, this is purely hypothetical and
needs to be further tested. Furthermore, duplications of this region
have been observed in proven fertile fathers in a diagnostic setting.
Therefore, it is less likely that the duplication of the CATSPER2 gene
will be causative for the maturation arrest observed in our patient.
Homozygous deletions of the CATSPER2 gene have been reported
to be related to male infertility due to the sperm immotility
(Carlson et al., 2005; Ho et al., 2009). The region in which this re-
arrangement was detected involved two more genes: CKMT1B and
STRC. A homozygous deletion involving the three genes has been
described in patients with male infertility and deafness (Avidan et al.,
2003; Zhang et al., 2007). In our control group, we did not find any
duplication as in patient EMA18, though two heterozygous deletions
were observed.
Another interesting region includes FAM82A1, at chromosomeband
2p22.2. For patient EMA18 a deletion was observed, including the
start codon and predicting a deletion of at least half of the protein
(328 amino acids). The remaining copy of the FAM82A1 gene
appeared to be intact in EMA18. The FAM82A1 gene has not been
studied before, and therefore an association with spermatogenesis
and male (in)fertility remains unknown.
On chromosome 12, we detected a deletion removing the complete
SIRT4 gene. The human SIRT4 gene is ubiquitously expressed, and loca-
lized in mitochondria (Haigis et al., 2006; Ahuja et al., 2007). The gene
SIRT4 is located at 12q24.31. It has ADP-ribosyltransferase activity and
is presumably involved in various metabolic processes (Yu and Auwerx,
2009). In the present study, a hemizygous deletion of this gene was only
detected in one infertile man, and not in normozoospermic controls.
However, knock-out mice models showed normal reproduction with
normal litter sizes, and therefore the deletion of one copy of this
gene might not be related to the fertility problems observed in this
patient (Haigis et al., 2006).
In a final rearrangement, the complete C17ORF51 gene is absent in
EMA2. In total, we have detected two controls with a duplication of
this region, but none with a deletion. The function of this gene also
remains to be investigated, so it is hard to anticipate the consequences
of a deletion. The remaining copy of the C17ORF51 gene remains
intact in patient EMA2.
Of the eight remaining regions, two regions are rearranged in
patient EMA18 (involving FAM82A1 and PLSCR2) and two regions
are duplicated in EMA8 (involving among others genes, THRAP3,
SH3D21 and CATSPER2). Although in patients with a maturation
arrest of spermatogenesis, a single gene defect is anticipated, we
should bear in mind that only the contribution of multiple regions
might be causative for the fertility problems. This should especially
be taken into consideration in patients with severe oligozoospermia.
Overall, three regions containing genes potentially involved in male
infertility were detected. Yet, the three genes (CATSPER2, PLSCR2
and SYT6) are involved in the last stages of spermatogenesis or
fertilization, and therefore it remains unsure whether duplications or
deletions of these genes are involved in a meiotic arrest at the
spermatocyte level. One more gene, SLC25A24, has a testis-enriched
expression pattern. This gene is a mitochondrial carrier and might
be involved in the transport of adenine nucleotides (Fiermonte
et al., 2004). It would be of particular interest to study the conse-
quences of a deletion of SLC25A24 in more detail. Three
more genes (C17ORF51, FAM82A1 and SH3D21) are also
interesting for further research studies, as their function remains to
be elucidated.
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This is the first study to investigate array CGH in patients with in-
fertility problems showing that potential causative factors can be
detected. Yet, more research is necessary for each region to prove
a link with male infertility. Furthermore, in this first study, we
focused on defects in protein coding genes, thereby excluding a
number of rearrangements such as intronic deletions and duplications,
non-coding RNAs, pseudogenes etc. Possibly, these rearrangements
might be the underlying cause of (part of) the fertility problems as
well. In future studies, these regions will be included in our analyses.
Moreover, some genes or regions are (currently) not possible to
examine since they are present in multiple copies.
As more studies will be performed on larger groups of normozoos-
permic controls, the knowledge on ‘neutral’ CNVs will increase. This
will make the interpretation of data obtained from patient studies
easier. Furthermore, larger studies on unselected groups of patients
(which at the same time requires the simultaneous analysis of controls)
will be useful to determine whether array CGH should be provided as
a routine test in the diagnosis of male infertility. However, currently it
is not useful to implement array CGH in a routine day-to-day clinical
practice. Nevertheless, this technique is useful in a research setting for
identifying genes that are essential for or at least involved in
spermatogenesis.
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